ATLANTA, Dec. 8 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics has been invited to participate in the Adams Harkness, “Trends in Inflammatory Disease” investor conference on Wednesday, December 14, 2005, at the Omni Berkshire Place in New York City.
About AtheroGenics
AtheroGenics is a pioneer in the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics’ lead compound, AGI-1067, is being evaluated in the pivotal Phase III clinical trial called ARISE, as an oral therapy for the treatment of atherosclerosis. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its novel vascular protectant(R) technology. For more information about AtheroGenics, please visit www.atherogenics.com.
AtheroGenics, Inc.
CONTACT: Donna L. Glasky of AtheroGenics, Inc., +1-678-336-2517, or email,investor@atherogenics.com; or Investor Relations, Lilian Stern of SternInvestor Relations, Inc., +1-212-362-1200, or email lilian@sternir.com; orMedia, Katie Brazel of Fleishman Hillard, +1-404-739-0150, or emailbrazelk@fleishman.com
Web site: http://www.atherogenics.com//
